Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- Roundtable Top Picks of the Week
- FED Front & Center Again
- RTI: Sector Strength Charts - Where's the Opportunity Now?
- Surging Financial ETFs Beating the Market
- Utility Industry Stock Outlook - June 2013
- 3 Japanese Stocks to Buy Now
- Your Next Stock Should Be Making New Highs
- Anatomy of Success: Stoneridge (SRI)
- RTI: What Will the Fed Do Wednesday?
- AWS 6/18: Can the Fed Afford to Keep the Suspense?
- PFP 6/18: Wednesday Fed Watch
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 06/18/2013
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
| ERICKSON AIR | EAC | 5.10% |
| ASSURED GUAR | AGO | 4.98% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Roche Holding AG (RHHBY) recently announced that the European Medicines Agency (EMA) has approved a label expansion for Pegasys in combination with ribavirin for the treatment of chronic hepatitis C virus (HCV) in children and adolescent five years and older.
We note that Pegasys plus antiviral ribavirin is approved for the treatment of chronic HCV, human immunodeficiency virus (HIV)/HCV co-infection and chronic hepatitis B in adults.
Children and adolescents aged five years or more who have not received prior treatment and have been tested positive can now be treated with Pegasys plus ribavirin. Roche had conducted a randomized controlled study based on which approval was granted.
The study results revealed that a larger percentage of children treated with the Pegasys plus ribavirin combination achieved sustained viral response than the children treated with Pegasys alone (53% versus 21%). The results in children and adolescents were similar to the results observed in adults infected with HCV genotype I.
We note that companies like Merck & Co. Inc. (MRK - Analyst Report) and Vertex Pharmaceuticals Inc. (VRTX - Snapshot Report) have a presence in the HCV market.
The label expansion on Pegasys into the children and adolescent population is a positive. Recently, Roche received US Food and Drug Administration (FDA) approval for a next-generation viral load test for use in chronic HCV patients. We are pleased with Roche’s progress in the treatment of HCV.
Roche currently carries a Zacks Rank #4 (Sell). Stocks which currently look well-positioned include Novo Nordisk (NVO - Analyst Report). Novo Nordisk carries a Zacks Rank #2 (Buy).
Get the full on RHHBY - FREE
Get the full Snapshot Report on VRTX - FREE
Get the full Analyst Report on NVO - FREE
Get the full Analyst Report on MRK - FREE